Clinical trials: in Cameroon
Snake Bites, Antivenins
Evaluation of Anti-venoms Serum in Africa
There is little or no assessment under real-use conditions of the efficacy and the tolerance in the short, medium and long term of the antivenoms currently on the market and used in the treatment of snake bites.
- Conditions
- Snake Bites, Antivenins, Snake Venoms
- Trial name
- ESAA (NCT03326492)
- Testing
- Antivenom serum Inoserp Pan-Africa® injection
- Where
- 13 sites in Cameroon
- Volunteers
- 474 people
- Sponsor
- Institut Pasteur
Simian Foamy Virus Infection (Disorder)
Simian Foamy Virus Transmission to Humans
About three quarters of the viral agents that have emerged recently in humans are considered to originate from other animals. These viruses have often evolved and spread into the human population through various mechanisms after…
- Trial name
- NCT03225794
- Testing
- Simian foamy virus Infection
- Where
- Cameroon
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Snake Bites
Safety and Effectiveness of PANAF-Premium TM Snake Venom Antiserum As Standard Treatment for Snakebites
Snakebite envenomation (SBE) is a major public health problem in many developing countries. Standard snake antivenom (SA) remains the primary treatment and has been shown to reduce mortality in observational studies conducted in…
- Trial name
- PMS (NCT06615960)
- Where
- Cameroon
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Premium Serums & Vaccines Pvt.Ltd.
Microcephaly, Congenital Infection
Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
This study will explore whether ZIKV is currently responsible for neurological complications, and particularly microcephaly, in Aedes-infested regions of Sub-Saharan Africa (SSA) and Asia.
- Trial name
- NCT03922594
- Testing
- Differential diagnosis for infectious causes of microcephaly
- Where
- 8 sites in Cameroon, China and 3 more
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur
Malaria,Falciparum
Cohort Event Monitoring Study of Pyramax®
The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes.
- Trial name
- NCT03201770
- Testing
- pyronaridine artesunate
- Where
- 5 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 8,572 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Plasmodium Falciparum Infection
Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
Primary objective: To assess the Day 28 efficacy defined as the percentage of patients with no parasitic recrudescence, of 3 treatment groups - 3 dose levels of ferroquine associated with artesunate - for a 3-day treatment.
- Trial name
- FARM (NCT00988507)
- Testing
- Ferroquine (SSR97193), artesunate
- Where
- 10 sites in Benin, Burkina Faso and 4 more
- Volunteers
- 440 people
- Sponsor
- Sanofi
Malaria
Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria
The present study aims to investigate and to assess possible neurological and neuropsychiatric events in young children in west Africa with uncomplicated P.
- Trial name
- NCT00978172
- Testing
- artesunate and mefloquine
- Where
- Cameroon
- Volunteers
- 220 people
- Sponsor
- Mepha Ltd.
Malaria
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on D28 of administration of Coarsucam™ (artesunate+amodiaquine fixed-dose combination), as a single daily dose, in…
- Trial name
- NCT00316329
- Testing
- Artesunate + Amodiaquine
- Where
- 5 sites in Cameroon, Madagascar and 2 more
- Volunteers
- 1,032 people
- Sponsor
- Sanofi
Malaria
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day 14, of administration of Arsucam® as a single daily intake versus two daily intakes.
- Trial name
- ATOL (NCT00445796)
- Testing
- Artesunate, Amodiaquine
- Where
- 2 sites in Cameroon, Senegal
- Volunteers
- 300 people
- Sponsor
- Sanofi
Plasmodium Falciparum Malaria
Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria
The purpose of this open randomised multi-centre clinical trial is to test the hypothesis that three pills of the fixed dose combination artesunate/sulfamethoxypyrazine/pyrimethamine, administered over 24 hours is not inferior in…
- Trial name
- NCT00484900
- Testing
- Co-Arinate FDC, Coartem
- Where
- 4 sites in Cameroon, Mali and 2 more
- Volunteers
- 1,390 people
- Sponsor
- Dafra Pharma